A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).
/in Hyperthermia, International Publications, Ovarian Cancer /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17032)Possible viral oncolysis by members of the Reoviridae and Paramyxoviridae families (an in vitro study).
/in International Publications, Newcastle Disease Virus /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e14212)Dynamics of the immune status in patients with cervical cancer receiving complex treatment with dendritic cell vaccine.
/in Cervical Cancer, Dendritic Cells /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17005)Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.
/in Dendritic Cells, NSCLC /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15783)Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15748)Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21025)Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21024)STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
/in Immunogenic Cell Death, International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2019-05-29 / Front Oncol 2019;9:436
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de